Log In


Reset Password
Opinion Editorial Cartoons Op-Ed Editorials Letters to the Editor

‘Inequity’ in cost of Alzheimer’s drug

Lecanameb, the newly FDA approved drug, is likely to cost about $27,000 a year, according to various websites. While some with Mild Cognitive Impairment can afford the drug, most cannot. This inequity is unconscionable in my mind. If you agree, please write or call Senators Michael Bennet and John Hickenlooper, and U.S. Rep. Lauren Boebert.

Feel free to use the following language, which comes from the Alzheimer’s Association, and please join me in writing our Legislatures to encourage “the Centers for Medicare & Medicaid Services (CMS) to provide full and unrestricted coverage for Food and Drug Administration (FDA)-approved Alzheimer’s treatments and to remove the requirements for Coverage with Evidence Development (CED) in its national coverage determination (NCD) for FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease.”

Kim Martin

Hesperus